Market Size & CAGR of Erythropoietin Stimulating Agents Market in 2021

Erythropoietin Stimulating Agents Market is expected to have a growth rate of 5.2% CAGR in 2021. The market size is projected to reach USD 2.5 billion by the end of 2021.

COVID-19 Impact on the Erythropoietin Stimulating Agents Market

The COVID-19 pandemic significantly impacted the Erythropoietin Stimulating Agents market as the focus shifted towards treating COVID-19 patients. As a result, the market witnessed a slight decline in sales and revenue during the peak of the pandemic.

Erythropoietin Stimulating Agents Dynamics

The dynamics of the Erythropoietin Stimulating Agents market are influenced by factors such as increasing prevalence of chronic kidney disease, rising demand for anemia treatment, and the introduction of innovative products by key market players.

Segments and Related Analysis

The Erythropoietin Stimulating Agents market is segmented based on type, application, and region. The key segments include Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, and others. By application, the market is divided into CKD, Cancer, and others.

By Region Analysis

The Erythropoietin Stimulating Agents market is analyzed across regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the market due to the high prevalence of CKD and cancer in the region.

Key Market Players and Competitive Landscape

Key market players in the Erythropoietin Stimulating Agents market include Amgen Inc., Johnson & Johnson, Roche, Pfizer, and Novartis. The market is highly competitive with companies focusing on product innovation and strategic partnerships.

Recent Happenings in the Erythropoietin Stimulating Agents Market

In recent developments, Amgen Inc. launched a new Erythropoietin Stimulating Agent for the treatment of anemia in cancer patients. Pfizer announced a collaboration with a biotech company to develop a novel Erythropoietin Stimulating Agent for CKD patients.